重组人B7-H1(PD-L1)

特别提示：包括重组人B7-H1(PD-L1)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人B7-H1(PD-L1)
英文名称：Recombinant Human Programmed Cell Death 1 Ligand 1

产品货号：重组人B7-H1(PD-L1)
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Phe19-Thr239在C端带Flag标签。

B7-H1/PD-L1质量控制：＞95%(还原性SDS-PAGE)

B7-H1/PD-L1制剂：冻干品

B7-H1/PD-L1保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

B7-H1/PD-L1复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于B7-H1/PD-L1：
CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

除了重组人B7-H1(PD-L1),，我公司还供应以下相关产品：
 

货号	名称	规格
JN0209	重组人TMIGD2	10μg|50μg|500μg|1mg
JN2026	重组人热反应蛋白12(HRSP12)	10μg|50μg|500μg|1mg
JN0747	重组人GMPR(GMP还原酶1)	10μg|50μg|500μg|1mg
JN0803	重组人尿斑蛋白2(尿路上皮分化特异糖蛋白2)(Uroplakin-2)	10μg|50μg|500μg|1mg
JN0861	重组人β-肌动蛋白(β-Actin)	10μg|50μg|500μg|1mg
JN0891	重组人谷胱甘肽S-转移酶ζ1(MAAI)	10μg|50μg|500μg|1mg
JN0916	重组人ZNF22(锌指蛋白22)	10μg|50μg|500μg|1mg
JN0977	重组人MCEE(甲基丙二酰辅酶A异构酶)	10μg|50μg|500μg|1mg
JN1186	重组人中性粒细胞明胶酶相关脂质运载蛋白(NGAL)(LCN2)	10μg|50μg|500μg|1mg
JN1295	重组小鼠基质金属蛋白酶12(MMP12)	10μg|50μg|500μg|1mg
JN1825	重组人CD83	10μg|50μg|500μg|1mg
JN1837	重组人FCAR	10μg|50μg|500μg|1mg
ZN1605	人CT-1重组蛋白	100ng
ZN1691	人OPG重组蛋白	100ng